Amylyx Pharmaceuticals, Inc.
AMLX
$14.46
$0.251.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -665.00K | 416.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -665.00K | 416.00K |
| Cost of Revenue | 19.86M | 27.22M | 22.12M | -13.31M | 58.25M |
| Gross Profit | -19.86M | -27.22M | -22.12M | 12.65M | -57.83M |
| SG&A Expenses | 16.17M | 15.64M | 15.68M | 17.10M | 17.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.03M | 42.86M | 37.80M | 39.99M | 76.08M |
| Operating Income | -36.03M | -42.86M | -37.80M | -40.65M | -75.66M |
| Income Before Tax | -34.39M | -41.44M | -35.91M | -38.18M | -72.70M |
| Income Tax Expenses | -- | -- | -- | -635.00K | -- |
| Earnings from Continuing Operations | -34.39M | -41.44M | -35.91M | -37.55M | -72.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.39M | -41.44M | -35.91M | -37.55M | -72.70M |
| EBIT | -36.03M | -42.86M | -37.80M | -40.65M | -75.66M |
| EBITDA | -35.91M | -42.72M | -37.65M | -40.49M | -75.44M |
| EPS Basic | -0.37 | -0.46 | -0.42 | -0.55 | -1.07 |
| Normalized Basic EPS | -0.23 | -0.29 | -0.26 | -0.44 | -0.67 |
| EPS Diluted | -0.37 | -0.46 | -0.42 | -0.55 | -1.07 |
| Normalized Diluted EPS | -0.23 | -0.29 | -0.26 | -0.44 | -0.67 |
| Average Basic Shares Outstanding | 93.33M | 89.14M | 85.70M | 68.59M | 68.09M |
| Average Diluted Shares Outstanding | 93.33M | 89.14M | 85.70M | 68.59M | 68.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |